Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 301 to 350 of 2013

TitleReference numberPublishedLast updated
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsTA948
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)TA945
Devices for remote monitoring of Parkinson's diseaseHTG657
COVID-19 rapid guideline: managing the long-term effects of COVID-19NG188
Pharyngeal electrical stimulation for neurogenic dysphagiaHTG709
Temperature control to improve neurological outcomes after cardiac arrestHTG710
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Sebelipase alfa for treating Wolman diseaseHST30
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Intravascular lithotripsy for calcified arteries in peripheral arterial diseaseHTG707
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)TA940
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Empagliflozin for treating chronic kidney diseaseTA942
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Risdiplam for treating spinal muscular atrophyTA755
Cardiovascular disease: risk assessment and reduction, including lipid modificationNG238
Digitally enabled therapies for adults with anxiety disorders: early value assessmentHTG676
Middle meningeal artery embolisation for chronic subdural haematomasHTG706
Velmanase alfa for treating alpha-mannosidosisHST29
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Acne vulgaris: managementNG198
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolismHTG705
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)TA932
Zanubrutinib for treating chronic lymphocytic leukaemiaTA931
Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosisHTG704
Transient loss of consciousness ('blackouts') in over 16sCG109
Hypertension in adults: diagnosis and managementNG136
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsTA930
Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessmentHTG701
Biodegradable subacromial spacer insertion for rotator cuff tearsHTG702
Extracorporeal carbon dioxide removal for acute respiratory failureHTG703
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerCG164
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodineTA928
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA929
Jaundice in newborn babies under 28 daysCG98
Ranibizumab for treating diabetic macular oedemaTA274
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditionsHTG699
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923
Stroke rehabilitation in adultsNG236
Rimegepant for treating migraineTA919
Tofacitinib for treating active ankylosing spondylitisTA920
Ruxolitinib for treating polycythaemia veraTA921

Results per page

  1. 10
  2. 25
  3. 50
  4. All